Abarca Health

Medicare Drug Negotiation Is the Model for the Future of Drug Pricing, Abarca CEO Says

For the first time ever, CMS is preparing to negotiate prices for drugs paid for by Medicare. This has sparked a huge debate — will the creation of this taxpayer-funded drug negotiation infrastructure be a failed experiment, or will it become the standard for the future of drug pricing in this country? Jason Borschow, president and CEO of Abarca Health, says it's the latter.

Outcome-based contracts likely to keep growing, evolving despite challenges

Although they've seen growth in the last few years, full implementation of outcome-based contracts faces hurdles like expensive technology, outmoded infrastructure and regulations that get in the way.